Literature DB >> 35312767

Sodium-Glucose Cotransporter 2 Inhibitors and Risk of Bladder and Renal Cancer: Scandinavian Cohort Study.

Peter Ueda1, Henrik Svanström1,2, Anders Hviid2,3, Björn Eliasson2,4, Ann-Marie Svensson4,5, Stefan Franzén5,6, Soffia Gudbjörnsdottir4,5, Kristian Hveem7,8, Christian Jonasson7,8,9, Viktor Wintzell1, Mads Melbye10,11, Björn Pasternak1,2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2022        PMID： 35312767      PMCID： PMC9174962          DOI： 10.2337/dc21-1917

Source DB:  PubMed          Journal:  Diabetes Care        ISSN： 0149-5992            Impact factor:   17.152


× No keyword cloud information.
  5 in total

1.  Sodium-glucose co-transporter-2 (SGLT-2) inhibitors and cancer: A meta-analysis of randomized controlled trials.

Authors:  Ilaria Dicembrini; Besmir Nreu; Edoardo Mannucci; Matteo Monami
Journal:  Diabetes Obes Metab       Date:  2019-05-01       Impact factor: 6.577

Review 2.  SGLT2 inhibitors and risk of cancer in type 2 diabetes: a systematic review and meta-analysis of randomised controlled trials.

Authors:  Huilin Tang; Qi Dai; Weilong Shi; Suodi Zhai; Yiqing Song; Jiali Han
Journal:  Diabetologia       Date:  2017-07-19       Impact factor: 10.122

3.  SGLT2 Inhibitors and Bladder Cancer: Analysis of Cases Reported in the European Pharmacovigilance Database.

Authors:  Montserrat García; Unai Arteche-Martinez; Unax Lertxundi; Carmelo Aguirre
Journal:  J Clin Pharmacol       Date:  2020-08-21       Impact factor: 3.126

4.  Use of sodium-glucose co-transporter 2 inhibitors and risk of serious renal events: Scandinavian cohort study.

Authors:  Björn Pasternak; Viktor Wintzell; Mads Melbye; Björn Eliasson; Ann-Marie Svensson; Stefan Franzén; Soffia Gudbjörnsdottir; Kristian Hveem; Christian Jonasson; Henrik Svanström; Peter Ueda
Journal:  BMJ       Date:  2020-04-29

5.  Use of incretin-based drugs and risk of cholangiocarcinoma: Scandinavian cohort study.

Authors:  Peter Ueda; Viktor Wintzell; Mads Melbye; Björn Eliasson; Ann-Marie Svensson; Stefan Franzén; Soffia Gudbjörnsdottir; Kristian Hveem; Christian Jonasson; Henrik Svanström; Björn Pasternak
Journal:  Diabetologia       Date:  2021-07-13       Impact factor: 10.122
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.